Erlotinib

InformationBDTX-189 is a potent and selective inhibitor of allostericEGFRandHER2oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2,BLKandRIPK2, reapectively. BDTX-189 exhibits anticancer activity.TargetsEGFR (Cell-free

InformationBDTX-189 is a potent and selective inhibitor of allostericEGFRandHER2oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2,BLKandRIPK2, reapectively. BDTX-189 exhibits anticancer activity.TargetsEGFR (Cell-free

InformationBDTX-189 is a potent and selective inhibitor of allostericEGFRandHER2oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2,BLKandRIPK2, reapectively. BDTX-189 exhibits anticancer activity.TargetsEGFR (Cell-free

InformationBDTX-189 is a potent and selective inhibitor of allostericEGFRandHER2oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2,BLKandRIPK2, reapectively. BDTX-189 exhibits anticancer activity.TargetsEGFR (Cell-free

InformationBDTX-189 is a potent and selective inhibitor of allostericEGFRandHER2oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2,BLKandRIPK2, reapectively. BDTX-189 exhibits anticancer activity.TargetsEGFR (Cell-free

An antagonist of ER&alpha that blocks 17&beta-estradiol-induced proliferation of drug-resistant cancer cell lines at concentrations ranging from 10 to 1,000 nM drives tumor regression in mice bearing MCF-7 xenografts inhibits ER&alpha-dependent

InformationBIX02188 is a selective inhibitor ofMEK5withIC50of 4.3 nM, also inhibits ERK5 catalytic activity withIC50of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.In vitroBIX02188 significantly blocks MEK5

A cell-permeable and irreversible inhibitor of EGF-receptor (EGFR) kinase activity in vivo (IC 50 = 250-490 pM) as well as EGF-stimulated autophosphorylation of tyrosine residues in the EGFR in vivo (IC 50 = 5 nM). Blocks EGF-mediated growth in

Coprelotamab (anti-ERBB2) is humanized monoclonal antibody targated against HER2 with the potential to treat breast cancer.

Coprelotamab (anti-ERBB2) is humanized monoclonal antibody targated against HER2 with the potential to treat breast cancer.

Coprelotamab (anti-ERBB2) is humanized monoclonal antibody targated against HER2 with the potential to treat breast cancer.

Coprelotamab (anti-ERBB2) is humanized monoclonal antibody targated against HER2 with the potential to treat breast cancer.